The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Karaseva V.V.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Tyulandin S.A.

National Medical Research Center for Oncology named after N. N. Blokhin, Moscow, Russia

The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia

Authors:

Frank G.A., Kuznetsova O.A., Zavalishina L.E., Andreeva Yu.Yu., Karaseva V.V., Tyulandin S.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2020;82(3): 5‑15

DOI: 10.17116/patol2020820315

Read: 6601 times

Download PDF (RU)
Contact the author
Table of contents

THE FIRST EXPERIENCE OF PD-L1 TESTING OF TRIPLE NEGATIVE BREAST CANCER WITH MARKER SP142 IN RUSSIA
THE FIRST EXPERIENCE OF PD-L1 TESTING OF TRIPLE NEGATIVE BREAST CANCER WITH MARKER SP142 IN RUSSIA

To cite this article:

Frank GA, Kuznetsova OA, Zavalishina LE, Andreeva YuYu, Karaseva VV, Tyulandin SA. The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia. Russian Journal of Archive of Pathology. 2020;82(3):5‑15. (In Russ.)
https://doi.org/10.17116/patol2020820315

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohe­sive gastric carcinomas. Russian Journal of Archive of Pathology. 2025;(2):11-17
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Correlation of tumor budding with DNA mismatch repair system and PD-L1-status in gastric cancer. Russian Journal of Archive of Pathology. 2025;(4):5-12
Abstract:

Aim of study — to evaluate the pecularities of PD-L1 expression in triple negative breast cancer (TNBC) in the Russian population.

Materials and methods. For 7 months, within a scientific study of the Russian Society of Clinical Oncology (RUSSCO), we determined the PD-L1 status of 58 patients with TNBC. In each case, an immunohistochemical study was performed in a closed Ventana Bench Mark Ultra automatic stainer using a closed protocol with rabbit monoclonal antibodies Ventana PD-L1 SP142 and Opti View DAB IHC Detection Kit with Opti View Amplification Kit.

Results. Positive PD-L1 status in TNBC was detected in 37.93% of cases. Almost all tumors had an expression level of up to 10%. Only 5.17% of cases showed ligand expression on tumor cells.

Conclusions. According to the results of the first experience of testing PD-L1 in TNLM in Russia, it was possible to obtain data comparable to the same data of large international studies. RUSSCO’s information and logistic support allows making this analysis available to all citizens of the country.

Keywords:

triple negative breast cancer
PD-L1
SP142

Authors:

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Karaseva V.V.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Tyulandin S.A.

National Medical Research Center for Oncology named after N. N. Blokhin, Moscow, Russia

Received:

05.02.2020

Accepted:

19.02.2020

Close metadata

References:

  1. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. https://doi.org/10.3389/fimmu.2019.02022
  2. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
  3. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313-1325. https://doi.org/10.1002/jcp.27172
  4. Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671-97682. https://doi.org/10.18632/oncotarget.18311
  5. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. https://doi.org/10.1186/s12943-018-0928-4
  6. Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26. https://doi.org/10.1038/s41392-018-0022-9
  7. Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25-34. https://doi.org/10.1111/his.12904
  8. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361-370. https://doi.org/10.1158/2326-6066.CIR-13-0127
  9. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015;6(28):26483-26493. https://doi.org/10.18632/oncotarget.4494
  10. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6(7):5449-5464. https://doi.org/10.18632/oncotarget.3216
  11. Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, Hiller L, Dunn J, Poole CJ, Bowden S, Earl HM, Pharoah PD, Caldas C. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26(7):1488-1493. https://doi.org/10.1093/annonc/mdv192
  12. Li S, Chen L, Jiang J. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Medicine(Baltimore). 2019; 98(16):e15201. https://doi.org/10.1097/MD.0000000000015201
  13. Guo Y, Yu P, Liu Z, Maimaiti Y, Wang S, Yin X, Liu C, Huang T. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis. PLoS One. 2016;11(5): e0156323. https://doi.org/10.1371/journal.pone.0156323
  14. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627-636. https://doi.org/10.1007/s10549-010-1293-1
  15. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121. https://doi.org/10.1056/NEJMoa1809615
  16. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. https://doi.org/10.1016/j.immuni.2013.07.012
  17. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030. https://doi.org/10.1200/JCO.2013.53.0105
  18. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase ib study. J Clin Oncol. 2017;35(19):2117-2124. https://doi.org/10.1200/JCO.2016.71.6795
  19. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119-3125. https://doi.org/10.1200/JCO.2016.67.9761
  20. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J Clin Oncol. 2016;34(8):833-842. https://doi.org/10.1200/JCO.2015.63.7421
  21. Ning YM, Suzman D, Maher VE, Zhang L, Tan S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, Kim G, Pazdur R. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist. 2017;22(6):743-749. https://doi.org/10.1634/theoncologist.2017-0087
  22. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
  23. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. https://doi.org/10.1186/s13045-019-0779-5
  24. Planes-Laine G, Rochigneux P, Bertucci F, Chrétien AS, Viens P, Sabatier R, Gonçalves A. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review. Cancers (Basel). 2019;11(7):1033. https://doi.org/10.3390/cancers11071033
  25. Vennapusa B, Baker B, Kowanetz M, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. Appl Immunohistochem Mol Morphol. 2019;27(2):92-100. https://doi.org/10.1097/PAI.0000000000000594
  26. Frank GA, Kuznetsova OA, Zavalishina LE, Andreeva YY, Moskvina LV. Study of the PD-L1 status in breast cancer, by using the SP142 monoclonal antibody, and the prospects for determining treatment policy Archive of Pathology/Arkhiv Patologii. https://doi.org/10.17116/patol2019810515
  27. Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019;19(3):227-233. https://doi.org/10.17305/bjbms.2019.4204
  28. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59. https://doi.org/10.1016/S1470-2045(19)30689-8
  29. Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras VC, Winer EP, Kockx M, Peeters D, Chui SY, Lin JC, Nguyen Duc A, Viale G, Molinero L, Emens LA. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Ann Oncol. 2019;30(5):858-859. https://doi.org/10.1093/annonc/mdz394.009
  30. Manson QF, Schrijver WAME, TerHoeve ND, Moelans CB, van Diest PJ. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clin Exp Metastasis. 2019;36(1):29-37. https://doi.org/10.1007/s10585-018-9950-6
  31. Ventana Medical Systems, Inc., Roche Diagnostics International, Inc. (Instruction for antibody SP142. 2017).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.